Rezolute Stock Surges 10.8% After 6 of 8 Tumour HI Patients Respond in Phase III
RZLT•In Rezolute’s second Phase III tumour hyperinsulinism trial, 6 of 8 patients achieved at least 50% reduction in intravenous glucose requirements within eight weeks and fully discontinued IV glucose. Rezolute’s Nasdaq-listed stock rose 10.8% on June 2, all six responders entered a six-month open-label extension and no drug-related safety events were reported.
1. Interim Phase III Tumour HI Results
Rezolute treated eight of the planned 16 tumour hyperinsulinism patients with ersodetug in its second Phase III trial (NCT06881992), with six meeting the primary endpoint of at least 50% reduction in glucose infusion rate within eight weeks and fully discontinuing intravenous glucose.
2. Stock Market Reaction and Open-Label Extension
Following announcement of these interim data, Rezolute’s Nasdaq-listed stock rose 10.8% on June 2 with an estimated 9.25% pre-market increase. All six responders opted into a six-month open-label extension and no drug-related safety events have been reported.
3. Context of Previous sunRIZE Trial Outcome
In December 2025, the company’s sunRIZE Phase III trial in pediatric congenital hyperinsulinism failed to meet primary or key secondary endpoints, triggering an almost 89% stock plunge and underscoring the importance of positive momentum in the current study.
